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The European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) was established to 
harmonise clinical antimicrobial breakpoints and to 
define breakpoints for new agents in Europe. Data from 
the European Antimicrobial Resistance Surveillance 
Network (EARS-Net) external quality assessment (EQA) 
exercises from 2009 to 2012, from the United Kingdom 
External Quality Assessment Scheme (UK NEQAS) from 
November 2009 to March 2013 and data collected by 
EUCAST through a questionnaire in the first quarter 
of 2013 were analysed to investigate implementation 
of EUCAST guidelines in Europe. A rapid change to 
use of EUCAST breakpoints was observed over time. 
Figures for implementation of EUCAST breakpoints at 
the end of the studied period were 61.2% from EARS-
Net data and 73.2% from UK NEQAS data. Responses 
to the EUCAST questionnaire indicated that EUCAST 
breakpoints were used by over 50% of laboratories 
in 18 countries, by 10 to 50% of laboratories in eight 
countries and by less than 10% in seven countries. The 
EUCAST disk diffusion method was used by more than 
50% of laboratories in 12 countries, by 10 to 50% of 
laboratories in ten countries and by less than 10% in 
eleven countries. EUCAST guidelines implementation 
is essential to ensure consistent clinical reporting of 
antimicrobial susceptibility results and antimicrobial 
resistance surveillance. 
Background
The use of common clinical breakpoints for antimi-
crobial susceptibility testing is important both for 
consistent clinical reporting of antimicrobial sus-
ceptibility and for international surveillance of the 
antimicrobial susceptibility of microorganisms. The 
principal objective of the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) [1] is to 
harmonise antimicrobial breakpoints in Europe and 
to define breakpoints for new agents in collaboration 
with the European Medicines Agency (EMA) [2] follow-
ing a standard operating procedure agreed between 
EUCAST and the EMA [3,4]. EUCAST was established 
by the European Society for Clinical Microbiology and 
Infectious Diseases (ESCMID) in 1997 [5]. The commit-
tee was restructured in the years 2001 and 2002 with 
the support and central involvement of the national 
breakpoint committees that were active in Europe, i.e. 
those in France, Germany, the Netherlands, Norway, 
Sweden and the United Kingdom, and has been in 
operation in its current form since 2002. EUCAST has 
a General Committee [6], which includes one repre-
sentative of each country from Europe and any country 
outside Europe interested in being part of the EUCAST 
process.
ESCMID has remained the administrative, financial and 
scientific platform of EUCAST throughout. Principal 
financial support over the years has been from ESCMID, 
European Union (EU) grants, a grant from the European 
Centre for Disease Prevention and Control (ECDC) and 
currently through a framework contract with the ECDC.
Today, EUCAST is well established as the only pan-
European antimicrobial breakpoint committee, with 
representatives throughout Europe and beyond. It is 
accepted as the European antimicrobial breakpoint 
committee by clinicians and clinical microbiologists, by 
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national breakpoint committees and medicines agen-
cies in Europe, the ECDC, the EMA, the European Food 
Safety Authority (EFSA), the pharmaceutical industry 
and diagnostic companies with interests in antimicro-
bial susceptibility testing. Of note, the EUCAST clinical 
breakpoints apply to antimicrobial resistance case def-
inition as reportable to the European Union (EU) sur-
veillance network for communicable diseases [7].
The breakpoint harmonisation process for all major 
groups of antimicrobial agents and organisms was 
completed in 2008/09. Since then there has been 
rapid adoption of EUCAST breakpoints and methods in 
Europe. Complete data on uptake in all European labo-
ratories are not available as in most countries there is 
no mechanism for collection of information on suscep-
tibility testing guidelines followed. A combination of 
different data sources needs to be used to obtain this 
information.
Analysed data sources
Data presented here are taken from three different 
sources. Firstly, the external quality assessment (EQA) 
exercise that is part of the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) [8] organ-
ised by ECDC though a framework contract with the 
UK National External Quality Assessment Scheme (UK 
NEQAS). Secondly, the international external qual-
ity assessment scheme run by UK NEQAS [9]. Thirdly, 
data collected by EUCAST in the first quarter of 2013 
through a questionnaire on guidelines and methods 
used in different countries.
EARS-Net external quality assessment
The ECDC EARS-Net resistance surveillance programme 
collects data from all EU countries, two European 
Economic Area countries (Norway and Iceland) [7], plus 
Bosnia, Croatia (also EU since 1 July 2014), Israel and 
Turkey between 2009 and 2011 only. The number of 
participating laboratories in each country varies, with 
a total of between 766 and 817 laboratories from 28 to 
30 countries participating in the annual EQA exercises 
between 2009 and 2012 [10–13]. As part of the EQA 
exercise information is collected on breakpoint guide-
lines followed and methods used.
UK NEQAS for antimicrobial susceptibility 
testing
The UK NEQAS EQA scheme [9] includes subscribing 
laboratories principally from European countries and, 
as with EARS-Net, the number of participating labo-
ratories in each country is variable. However, the dis-
tribution of numbers of laboratories among countries 
differs from that of EARS-Net, with a total of between 
632 and 656 laboratories participating in the EQA 
scheme between November 2009 and March 2013. In 
the UK NEQAS for antimicrobial susceptibility testing 
two organisms of a variety of species are distributed 
each month. The number of participating laboratories 
returning results varies with the organism and antimi-
crobial agent so for consistency the data are based on 
results returned for E. coli isolates tested against cip-
rofloxacin, one of the most widely tested combinations. 
For each organism distributed, information is collected 
on breakpoint guidelines followed and methods used.
EUCAST questionnaire on guidelines and 
methods used in different countries
In the first quarter of 2013, a questionnaire was dis-
tributed to all General Committee members with the 
objective of collecting information on whether EUCAST 
breakpoint guidelines were followed, adoption of the 
EUCAST disk diffusion method and whether the coun-
try has a national antimicrobial susceptibility commit-
tee (NAC) as recommended by EUCAST [14]. At that time 
there were 35 countries with national representatives 
on the EUCAST General Committee, Australia, Austria, 
Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, 
Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Iceland, Ireland, Israel, 
Italy, Latvia, Lithuania, Luxemburg, the Netherlands, 
Norway, Poland, Portugal, Romania, Russia, Serbia, 
Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey 
and the United Kingdom. In most countries there is no 
official requirement for laboratories to follow any par-
ticular breakpoint guidelines and a variety of meth-
ods is used. Also most countries have no mechanism 
for collecting precise information on guidelines and 
methods used, and this may be continually changing 
as individual laboratories make decisions to change 
susceptibility testing guidelines followed or methods 
used. Therefore, the General Committee representa-
tives were asked to provide estimates of the propor-
tions of laboratories falling into broad categories for 
use of EUCAST guidelines and the EUCAST disk diffu-
sion method. The categories provided were below 10%, 
10 to 50% and above 50% of laboratories.
Results
Data from EARS-Net (Table) show a decline in use of 
the Clinical and Laboratory Standards Institute (CLSI, 
United States) breakpoints from 67.5% in September 
2009 to 38.4% in May 2012, and an increase in use 
of EUCAST breakpoints from 22.2% in 2009 to 61.2% 
in 2012. Some national guidelines such as the British 
Society for Antimicrobial Chemotherapy (BSAC, United 
Kingdom) [15] and the Comité de l’Antibiogramme de la 
Société Française de Microbiologie (CA-SFM, France) 
[16] have adopted EUCAST MIC breakpoints and ini-
tially calibrated their own disk diffusion method to 
the EUCAST breakpoints, so they were using EUCAST-
related methods and are therefore also counted as 
using EUCAST breakpoints. Both BSAC and CA-SFM are 
now in the process of changing to the EUCAST disk dif-
fusion method.
Data from UK NEQAS EQA (Table) show a similar decline 
in use of CLSI breakpoints as seen in EARS-Net, from 
58.5% in November 2009 to 26.8% in March 2013 and 
an increase in use of EUCAST breakpoints, from 36.1% 
to 73.2% over the same period. As with EARS-Net 
data, some national guidelines have adopted EUCAST 
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MIC breakpoints and are therefore counted as using 
EUCAST breakpoints.
Questionnaires were completed by 33 of the 35 General 
Committee representatives. Countries with a NAC are 
shown in Figure 1. At the time of the survey, 25 of the 
responding countries had an established NAC, four 
were in the process of setting up a NAC and four had no 
NAC. Use of EUCAST breakpoint guidelines is shown in 
Figure 2. EUCAST breakpoints were used by more than 
50% of laboratories in 18 countries, by 10 to 50% of 
laboratories in eight countries and by less than 10% in 
seven countries. Use of EUCAST disk diffusion method 
is shown in Figure 3. The EUCAST disk diffusion method 
was used by more than 50% of laboratories in 12 coun-
tries, by 10 to 50% of laboratories in ten countries and 
by less than 10% in eleven countries.
Discussion
Collection of reliable data on use of clinical breakpoint 
guidelines and methods for antimicrobial susceptibil-
ity testing in different countries is difficult because 
in most countries there is no national requirement to 
follow particular guidelines or methods, there are no 
mechanisms in place to collect such data, and the situ-
ation may change gradually over time as laboratories 
decide to change guidelines or methods. However, 
the findings from three independent data sources pre-
sented here consistently show that there has been 
widespread adoption of EUCAST breakpoints in recent 
years across clinical laboratories in the majority of 
European countries. The EQA exercises organised by 
EARS-Net and UK NEQAS include different but over-
lapping sets of laboratories covering most European 
countries. These EQA exercises show similar trends 
towards adoption of EUCAST breakpoints since 2009, 
with the UK NEQAS data indicating that over 70% of the 
laboratories providing data used EUCAST breakpoints 
in March 2013. The adoption of EUCAST guidelines has 
been mirrored by a decline in the use of CLSI break-
points. This process has been fuelled by the adoption 
of EUCAST breakpoints by EMA in 2005 [3] as part of the 
official European process for marketing authorisation 
of antimicrobial agents, the adoption of EUCAST break-
points by the European Commission Decision on case 
definition for surveillance of antimicrobial resistance in 
humans in 2012 [7], as well as the strong support by 
ESCMID and ECDC for use of EUCAST breakpoints for 
surveillance. Moreover, in some countries, the posi-
tion taken by national societies of clinical microbiology 
and/or infectious diseases has had a positive impact.
The rate of adoption of EUCAST breakpoints has been 
variable in different countries, as illustrated by the 
results from the EUCAST survey early in 2013. While 
in just over half of the countries surveyed the major-
ity of laboratories have adopted EUCAST breakpoints, 
in others the proportion of laboratories using EUCAST 
Table 
Antimicrobial susceptibility testing guidelines used by laboratories participating in the EARS-Net EQA exercises, 2009–2012 
and UK NEQAS for antimicrobial susceptibility testing, 2009–2013
Data source
Date,
number of laboratories
Percentage of laboratories using indicated guidelines
CLSI EUCAST and EUCAST-based
Othera/
combined/
not stated
EARS-Net EQA
September 2009 
n = 775 67.5 22.2 10.3
June 2010 
n = 766 65.8 28.7 5.5
May 2011 
n = 817 46.8 47.6 5.6
May 2012 
n = 807 38.4 61.2 0.4
UK NEQAS EQA
November 2009
n = 651 58.8 36.1 5.1
November 2010 
n = 656 51.5 42.2 6.3
November 2011 
n = 643 36.8 58.6 4.6
April 2012 
n = 632 31.8 68.2 0
March 2013 
n = 650 26.8 73.2 0
CLSI: Clinical and Laboratory Standards Institute; EARS: European Antimicrobial Resistance Surveillance Network; EQA: external quality 
assessment; EUCAST: European Committee on Antimicrobial Susceptibility Testing; UK NEQAS: United Kingdom External Quality 
Assessment Scheme. 
a Other guidelines are local methods not complying with EUCAST or CLSI recommendations.
Figure 1
Countries with National Antimicrobial Susceptibility Testing Committees, EUCAST survey 2013
 NAC established  NAC formation
 in Progress
 No NAC  No Information
Switzerland
Luxembourg
Belgium
Netherlands
United 
Kingdom
Ireland
Iceland
Norway
Sweden
Finland
Russia
Estonia
Latvia
Lithuania
Poland
Czech Republic
Hungary
Slovakia
Slovenia
Croatia
Serbia
Montenegro
Albania
former Yugoslav 
Republic of 
Macedonia
Moldova
Ukraine
Greece
TurkeyItaly
France
Spain
Portugal
Cyprus
Syria
Lebanon
Israel
Belarus
Bulgaria
Romania
Bosnia and 
Herzegovia
Austria
Germany
Australia (has NAC) is not on this map.
EUCAST: European Committee on Antimicrobial Susceptibility Testing, NAC: National Antimicrobial Susceptibility Testing Committee.
Figure 2
Use of EUCAST breakpoint guidelines in different countries, EUCAST survey 2013
 No Information >50% laboratories  10 to 50% laboratories  <10% laboratories
Switzerland
Luxembourg
Belgium
Netherlands
United 
Kingdom
Ireland
Iceland
Norway
Sweden
Finland
Russia
Estonia
Latvia
Lithuania
Poland
Czech Republic
Hungary
Slovakia
Slovenia
Croatia
Serbia
Montenegro
Albania
Moldova
Ukraine
Greece
TurkeyItaly
France
Spain
Portugal
Cyprus
Syria
Lebanon
Israel
Belarus
Bulgaria
Romania
Bosnia and 
Herzegovia
Austria
Germany
former Yugoslav 
Republic of 
Macedonia
Australia (10 to 50% laboratories) is not on this map.
EUCAST: European Committee on Antimicrobial Susceptibility Testing.
Figure 3
Use of the EUCAST disk diffusion method in different countries, EUCAST survey 2013 
 No Information >50% laboratories  10 to 50% laboratories  <10% laboratories
Switzerland
Luxembourg
Belgium
Netherlands
United 
Kingdom
Ireland
Iceland
Norway
Sweden
Finland
Russia
Estonia
Latvia
Lithuania
Poland
Czech Republic
Hungary
Slovakia
Slovenia
Croatia
Serbia
Montenegro
Albania
Moldova
Ukraine
Greece
TurkeyItaly
France
Spain
Portugal
Cyprus
Syria
Lebanon
Israel
Belarus
Bulgaria
Romania
Bosnia and 
Herzegovia
Austria
Germany
former Yugoslav 
Republic of 
Macedonia
Australia (10 to 50% laboratories) is not on this map.
EUCAST: European Committee on Antimicrobial Susceptibility Testing.
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breakpoints is still small. It is expected that the uptake 
of guidelines will be gradual as laboratories make the 
decision to change breakpoints and incorporate break-
points into local methods and information systems. 
The existence of a NAC to provide national guidance 
on antimicrobial susceptibility testing breakpoints 
and methods might have a substantial impact on labo-
ratory practices. EUCAST has actively promoted the 
establishment of NACs in countries where no such 
group existed. The EUCAST survey shows that most 
countries now have a NAC or are in the process of set-
ting up a NAC, and it is likely that these committees 
will positively influence the uptake of EUCAST guide-
lines. Furthermore, adoption of EUCAST breakpoints by 
public health microbiology national reference laborato-
ries participating in ECDC-supported external quality 
assessment programmes will encourage alignment of 
testing practice across the EU. In addition, free access 
to EUCAST breakpoint documents via the internet and 
implementation of EUCAST breakpoints in automatic 
susceptibility testing devices facilitate the wide adop-
tion of EUCAST guidelines.
Any standardised antimicrobial susceptibility testing 
method may be calibrated to EUCAST MIC breakpoints 
and national disk diffusion methods in France and the 
UK have been calibrated in this way [17,18]. However, 
there has been widespread demand for a EUCAST disk 
diffusion method and a EUCAST disk diffusion method 
was released in 2010 and published in 2014 [19]. The 
EUCAST 2013 survey has shown that, as with the uptake 
of EUCAST breakpoints, adoption of EUCAST disk diffu-
sion method has been variable in different countries, 
but is used in a considerable proportion of laborato-
ries in two thirds of surveyed countries. In many labo-
ratories, the main antimicrobial susceptibility testing 
method is an automated system and delays in the 
implementation of EUCAST breakpoints in automated 
systems have delayed adoption of EUCAST breakpoints 
in some laboratories. However, the majority of EUCAST 
breakpoints are now implemented in automated sys-
tems [20] and laboratories can choose to use EUCAST 
breakpoints in their automated systems.
The information on uptake of EUCAST guidelines from 
EARS-Net and EUCAST relates only to clinical laborato-
ries and the UK NEQAS EQA scheme includes greater 
than 95% of clinical laboratories. Information on guide-
lines followed in veterinary and food safety laborato-
ries has not been surveyed by EUCAST but it would be 
useful to do so in collaboration with veterinary and 
food safety networks.
It is clear that there has been a rapid change to use of 
EUCAST breakpoints over the last few years and there 
are indications that this trend is continuing as EUCAST 
breakpoints are increasingly referred to in scientific 
communications. The wide adoption of EUCAST break-
points will result in increased consistency of reporting 
of antimicrobial susceptibility testing results in differ-
ent countries and better comparability of antimicrobial 
resistance surveillance data among countries. Annual 
monitoring of progress in implementation of EUCAST 
breakpoints across clinical and reference laboratories 
in Europe will be conducted jointly by EUCAST and 
ECDC as a key public health microbiology performance 
indicator. 
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